Nature Clinical Practice Oncology - Table of Contents alert Volume 6 Issue 2

TABLE OF CONTENTS February 2009 Volume 6 Number 2 In this issue Editorial Research Highlights Practice Points Viewpoint Reviews Case Study Article Response Sign up for e-alerts Recommend to your library Web feeds Available online only Subscribe Advertisement Nature Publishing Group and The American Journal of Gastroenterology are pleased to introduce gastrojobs   Powered by naturejobs, the award-winning scientific and medical career placement service, gastrojobs is a unique, highly targeted site dedicated to recruiting the best researchers and medical professionals specializing in gastroenterology and hepatology.   Have your vacancies seen by the right candidates for FREE.   Visit gastrojobs to get started. "Officially endorsed by the European School of Oncology" EDITORIAL Top News the public should rely on Vincent T DeVita Jr doi:10.1038/ncponc1301 | Full Text | PDF RESEARCH HIGHLIGHTS Top PET predicts progression or relapse in patients with advanced Hodgkin lymphoma doi:10.1038/ncponc1284 | Full Text | PDF Novel gene signature predicts outcome in patients with cytogenetically normal AML doi:10.1038/ncponc1285 | Full Text | PDF Computer-aided detection is an alternative to double-reading mammography doi:10.1038/ncponc1290 | Full Text | PDF Obesity and high C-peptide levels predict worse outcome in men with prostate cancer doi:10.1038/ncponc1291 | Full Text | PDF Use of surrogate end points for prostate cancer-related mortality in clinical trials doi:10.1038/ncponc1292 | Full Text | PDF Linear mixed model helps to quantify PSA profile and predict disease progression doi:10.1038/ncponc1304 | Full Text | PDF Gene-expression profiles in fixed tissues correlate with survival in patients with HCC doi:10.1038/ncponc1305 | Full Text | PDF Circulating cancer cells predict relapse in patients with gastric cancer and CRC doi:10.1038/ncponc1306 | Full Text | PDF Best practice in the management of malignant germ-cell tumors of the ovary doi:10.1038/ncponc1307 | Full Text | PDF PRACTICE POINTS Top Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma? Keith T Flaherty and Weijing Sun doi:10.1038/ncponc1299 | Full Text | PDF How does extended lymphadenectomy influence practical care for patients with gastric cancer? Ilfet Songun and Cornelis JH van de Velde doi:10.1038/ncponc1300 | Full Text | PDF Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy Giovanni Martinelli, Simona Soverini, Ilaria Iacobucci and Michele Baccarani doi:10.1038/ncponc1276 | Full Text | PDF Does pegylated interferon -2b confer additional benefit in the adjuvant treatment of high-risk melanoma? John M Kirkwood, Hussein A Tawbi, Ahmad A Tarhini and Stergios J Moschos doi:10.1038/ncponc1297 | Full Text | PDF VIEWPOINT Top Should routine breast cancer staging include MRI? Monica Morrow doi:10.1038/ncponc1280 | Full Text | PDF REVIEWS Top Prophylactic and therapeutic anticoagulation for thrombosis—major issues in oncology Marc Carrier and Agnes YY Lee doi:10.1038/ncponc1244 | Full Text | PDF Epothilones: tubulin polymerization as a novel target for prostate cancer therapy James J Lee and W Kevin Kelly doi:10.1038/ncponc1281 | Full Text | PDF Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer Gabriella Mariani, Angelica Fasolo, Elena De Benedictis and Luca Gianni doi:10.1038/ncponc1298 | Full Text | PDF Melanoma biomarkers: current status and vision for the future Allison R Larson, Eliz Konat and Rhoda M Alani doi:10.1038/ncponc1296 | Full Text | PDF CASE STUDY Top A case of prolonged disease-free survival in a patient with choroidal metastasis from breast cancer Raymond W Jang, Mary Doherty, J Jill Hopkins and Ellen Warner doi:10.1038/ncponc1294 | Full Text | PDF ARTICLE RESPONSE Top Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer' Nicolas André and Eddy Pasquier doi:10.1038/ncponc1317 | Full Text Top Advertisement Announcing an open access option in British Journal of Cancer.   An open access option is now available to all authors of original research papers that are accepted for publication in BJC. BJC OPEN articles will be freely accessible to all readers immediately on publication.   Learn more about BJC OPEN by visiting BJC online at www.bjcancer.com. Full text content of the January 2009 issue is freely available in both HTML and PDF formats. Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Nature Clinical Practice Oncology. To purchase a subscription, please visit secure.nature.com/subscribe/ncponc You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.